Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
暂无分享，去创建一个
I. Pavord | C. Brightling | A. Wardlaw | V. Mistry | S. Gonem | B. Holzhauer | M. Bourne | A. Mansur | R. Hartley | S. Siddiqui | Richard A Kay | A. Singapuri | R. Berair | G. Bacher | Marie Laurencin | M. Laurencin